SCHEMBL1167198

SCHEMBL1167198

CC1(C)Oc2ccc(C(=O)n3nc(Nc4ccc(N5CCCC5)cc4)nc3N)cc2NC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ INSR P06213 1/20 0.48
▸ AXL P30530 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NPC1 O15118 1/20 0.41
▸ JAK1 P23458 4/20 0.40
▸ JAK2 O60674 3/20 0.40
▸ TYK2 P29597 3/20 0.40
▸ JAK3 P52333 3/20 0.40
▸ CCNB2 O95067 2/20 0.40
▸ CDK1 P06493 2/20 0.40
▸ CCNB1 P14635 2/20 0.40
▸ CCNB3 Q8WWL7 2/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1168324 0.94 AXL (0.51) POLBHPGDINSRAXLKDM4E
SCHEMBL1168175 0.87 POLB (0.48) POLBHPGDINSRAXLKDM4E
SCHEMBL1168078 0.84 AXL (0.50) POLBHPGDINSRAXL
SCHEMBL1167493 0.83 KDM4E (0.46) POLBHPGDKDM4EALDH1A1SMN1; SMN2
SCHEMBL1167950 0.81 HPGD (0.48) POLBHPGDINSRAXLKDM4E
SCHEMBL1167545 0.80 KDM4E (0.44) POLBHPGDINSRAXLKDM4E
SCHEMBL1168525 0.79 KDM4E (0.43) POLBHPGDKDM4EALDH1A1SMN1; SMN2
SCHEMBL1167539 0.78 INSR (0.55) INSRAXLKDM4EALDH1A1SMN1; SMN2
SCHEMBL1167671 0.76 JAK2 (0.60) INSRAXLKDM4EALDH1A1JAK1
SCHEMBL1167659 0.76 INSR (0.53) INSRAXLKDM4EALDH1A1JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 — — US claimed
US-8389557-B2 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2013-03-05 — — US disclosed
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2011-04-07 — — US disclosed
US-7884119-B2 protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation RIGEL PHARMACEUTICALS, INC. (US) 2011-02-08 — — US disclosed
EP-1922310-A2 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2008-05-21 — — EP disclosed
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2007-09-13 — — US disclosed
WO-2007030680-A2 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2007-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082131-A1 TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS AXL, TYRO3, FLT3 POLB 3121/4885HPGD 3210/4885INSR 508/4885
US-20070213375-A1 Triazole derivatives useful as Axl inhibitors AXL, TYRO3, FLT3 POLB 4096/4885HPGD 3260/4885INSR 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback